John Docherty - Oct 26, 2023 Form 4 Insider Report for Lexaria Bioscience Corp. (LEXX)

Role
President, Director
Signature
/John Docherty/
Stock symbol
LEXX
Transactions as of
Oct 26, 2023
Transactions value $
$0
Form type
4
Date filed
10/30/2023, 12:47 PM
Previous filing
Aug 29, 2022
Next filing
May 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LEXX common shares 54.1K Oct 26, 2023 Private Holding Company

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LEXX Stock Options Award $0 +30K +31.69% $0.00 125K Oct 26, 2023 Common Shares 30K $1.15 Direct
holding LEXX Stock Options 13.3K Oct 26, 2023 Common Shares 13.3K $3.00 Direct F1
holding LEXX Stock Options 31.3K Oct 26, 2023 Common Shares 18K $3.00 Direct F2
holding LEXX Stock Options 49.7K Oct 26, 2023 Common Shares 18.3K $3.00 Direct F3
holding LEXX Stock Options 64.7K Oct 26, 2023 Common Shares 15K $3.00 Direct F4
holding LEXX Stock Options 94.7K Oct 26, 2023 Common Shares 30K $2.91 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Repriced from $9.60 pursuant to shareholder approval received on May 9, 2023
F2 Repriced from $5.31 pursuant to shareholder approval received on May 9, 2023
F3 Repriced from $7.08 pursuant to shareholder approval received on May 9, 2023
F4 Repriced from $6.23 pursuant to shareholder approval received on May 9, 2023